Related Experiment Video
Updated: Aug 3, 2026
Combining Peripheral Nerve Grafting and Matrix Modulation to Repair the Injured Rat Spinal Cord
Published on: November 20, 2009
Targeting Rho to stimulate repair after spinal cord injury
Lisa McKerracher1, Haruhisa Higuchi
1Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Québec, Canada. lisa.mckerracher@umontreal.ca
Abstract:
Rho is an important signaling target to promote repair following spinal cord injury (SCI). Myelin-derived inhibitory proteins, as well as other classes of known growth inhibitory proteins, block regeneration by signaling activation of Rho. Here, we review the molecular mechanisms of Rho activation after SCI and explain known Rho signaling antagonists. We review the data on use of Rho antagonists to promote axon regeneration, neuroprotection, and functional recovery after SCI. We report on efforts to translate the nonclincal studies on rodents to clinical trials in patients with acute SCI.
Insights
Rho signaling activation inhibits repair after spinal cord injury (SCI). This review explores Rho antagonists for promoting axon regeneration, neuroprotection, and functional recovery, with efforts to translate rodent studies to human clinical trials.
Area of Science:
- Neuroscience
- Cell Signaling
- Regenerative Medicine
Background:
- Spinal cord injury (SCI) triggers inhibitory signaling pathways.
- Myelin-derived and other inhibitory proteins activate Rho signaling, hindering neural repair.
- Rho GTPases are critical regulators of the actin cytoskeleton and cell motility.
Purpose of the Study:
- To review the molecular mechanisms of Rho activation post-SCI.
- To discuss known Rho signaling antagonists and their therapeutic potential.
- To examine the translation of preclinical findings to clinical applications for acute SCI.
Main Methods:
- Literature review of molecular mechanisms of Rho activation in SCI.
- Analysis of studies investigating Rho antagonists for neuroprotection and regeneration.
- Evaluation of preclinical data and translation to clinical trials.
Main Results:
- Rho activation is a key mechanism by which inhibitory proteins block axon regeneration after SCI.
- Rho antagonists demonstrate potential in promoting axon regeneration, neuroprotection, and functional recovery in preclinical models.
- Clinical translation efforts are underway to test Rho antagonists in patients with acute SCI.
Conclusions:
- Targeting Rho signaling offers a promising therapeutic strategy for spinal cord injury.
- Further research and clinical trials are essential to validate the efficacy of Rho antagonists in humans.
- Successful translation could significantly improve outcomes for SCI patients.
